Protagonist Therapeutics: Two Slam Dunk Sets Of Pivotal Data Set Up Bull Case
…
50,660$
0,90%
Echtzeit-Aktienkurs Protagonist Therapeutics
Bid:
Ask:
Nachrichten zur Protagonist Therapeutics Aktie
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do…
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this…
Protagonist Therapeutics (PTGX) Upgraded to Buy: Heres Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
Protagonist Therapeutics: Transformation des Gesundheitswesens mit erstklassigen Peptidmedikamenten
Protagonist Therapeutics ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung und Entwicklung von peptidbasierten Therapeutika konzentriert.…
Truist raises Protagonist Therapeutics target to $76 By Investing.com
Truist raises Protagonist Therapeutics target to $76…
4 Stocks to Buy for Attractive Earnings Acceleration
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for…
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN),…